LAUSR

COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid Dear Editor, Since the new SARS-CoV-2 infection began, physicians have been concerned about the behavior of this novel disease in their patients, especially those with immunosuppressant treatment. In Spain, more than 250,000 cases had been confirmed at the end of May, nearly 65,000 of them in Madrid. In patients with moderatesevere psoriasis, continuous treatment is essential for appropriate disease control. There are multiple therapies with specific biological agents against cytokines or immunosuppressant treatments, which increase the risk of complications and infections. It remains unknown how coronavirus impacts psoriasis, and there is not enough data concerning the risks or benefits of stopping the medication during the disease. Initial reports suggest it might not worsen the prognosis compared to that of other patients. We performed a retrospective observational study including patients with psoriasis with systemic treatments in our hospital